umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC
Show others and affiliations
2005 (English)In: Int J Gynecol Cancer: Supplement 3, Vol. 15, 224-225 p.Article in journal (Refereed) Published
Place, publisher, year, edition, pages
2005. Vol. 15, 224-225 p.
Identifiers
URN: urn:nbn:se:umu:diva-14321OAI: oai:DiVA.org:umu-14321DiVA: diva2:153992
Available from: 2007-02-23 Created: 2007-02-23 Last updated: 2011-01-12Bibliographically approved

Open Access in DiVA

No full text

Search in DiVA

By author/editor
Boman, Karin
By organisation
Oncology

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 65 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf